Yasheng Pharmaceutical (6855.HK): Multiple Indications Continue to Accelerate Overseas Progress
Yasheng Pharmaceutical-B (06855.HK): Nellick's revenue increased year-on-year, and the core pipeline progressed smoothly
Yasheng Pharmaceutical-B (06855.HK): After Nellick's medical insurance, two phase 3 registered clinical trials were carried out steadily
Yasheng Pharmaceutical (06855.HK): Nellick's revenue is growing steadily, APG-2575 has been approved by the FDA to launch the third phase of the global registered clinical trial
Yasheng Pharmaceutical (6855.HK): Orebatinib dosage is clearly accelerating the internationalization process
Yasheng Pharmaceutical-B (06855.HK): International Phase III Approved, APG-2575 Accelerated Globalization
Yasheng Pharmaceutical-B (6855.HK): The amount of orebatinib released is imminent, and the clinical progress of the major new drug is progressing smoothly
Yasheng Pharmaceutical (6855.HK): Xiao He Cai shows great potential on the proximal keratocyte apoptosis circuit
Yasheng Pharmaceutical-B (06855.HK): Nalicke's accelerated release performance is in line with expectations
Yasheng Pharmaceutical-B (06855.HK): Nalicke's sales volume is impressive and continues to build differentiated pipelines
Yasheng Pharmaceutical-B (06855.HK): Nalick's commercialization is progressing smoothly and investment in innovation continues to increase
Yasheng Pharmaceutical-B (06855.HK): Commercialization of orebatinib is steadily advancing, and key drug candidates are progressing smoothly
Yasheng Pharmaceutical (6855.HK): Focus on the future leader in the field of apoptosis segmentation
Yasheng Pharmaceutical-B (6855.HK): Olevatinib has been approved for marketing, and clinical progress is progressing smoothly as the core product
Yasheng Pharmaceutical-B (06855.HK): The initial sales situation after Nalick's listing is impressive, and the company has officially entered the commercialization stage
Yasheng Pharmaceutical (06855.HK): APG-1252 shows potential to treat drug resistance with ocitinib
Yasheng Pharmaceutical-B (06855.HK) 2021 Interim Report Review: Clinical Development Comprehensively Promotes Strategic Cooperation to Help the Commercialization Process
Yasheng Pharmaceutical-B (06855.HK): R&D and BD progress are promising, the harvest period is approaching
Yasheng Pharmaceutical-B (6855.HK): Pipeline R&D is progressing steadily
Yasheng Pharmaceutical (06855.HK): Cell Apoptosis Track Leader
No Data